[
  {
    "ts": "2025-12-11T05:08:28+00:00",
    "headline": "How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating",
    "summary": "Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer expectations for revenue growth are set against a more supportive backdrop for U.S. drug pricing and renewed interest in large cap biopharma, helping to stabilize the valuation case. As these shifts play out alongside evolving views on Pfizer’s pipeline and deal making, investors can follow the...",
    "url": "https://finance.yahoo.com/news/narrative-surrounding-pfizer-changing-obesity-050828048.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "dfa4cf20-3643-38c6-9153-9998f205a1b6",
      "content": {
        "id": "dfa4cf20-3643-38c6-9153-9998f205a1b6",
        "contentType": "STORY",
        "title": "How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating",
        "description": "",
        "summary": "Pfizer's latest narrative update leaves its fair value estimate steady at about $29.08 per share, even as analysts fine tune assumptions around the company’s long term trajectory. Slightly softer expectations for revenue growth are set against a more supportive backdrop for U.S. drug pricing and renewed interest in large cap biopharma, helping to stabilize the valuation case. As these shifts play out alongside evolving views on Pfizer’s pipeline and deal making, investors can follow the...",
        "pubDate": "2025-12-11T05:08:28Z",
        "displayTime": "2025-12-11T05:08:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/narrative-surrounding-pfizer-changing-obesity-050828048.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/narrative-surrounding-pfizer-changing-obesity-050828048.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-11T11:00:00+00:00",
    "headline": "IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma",
    "summary": "IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free",
    "url": "https://finance.yahoo.com/news/ideaya-biosciences-completes-targeted-full-110000631.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "2cea7f3e-d324-358b-ac49-3b584c288fec",
      "content": {
        "id": "2cea7f3e-d324-358b-ac49-3b584c288fec",
        "contentType": "STORY",
        "title": "IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma",
        "description": "",
        "summary": "IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced it has completed its targeted full enrollment of 435 patients in the registration-enabling Phase 2/3 trial (OptimUM-02) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib, an oral c-MET inhibitor, in first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM). IDEAYA expects to report median progression-free",
        "pubDate": "2025-12-11T11:00:00Z",
        "displayTime": "2025-12-11T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/74efd2e2f7cc28d3a6ce5efb40fb6e7d",
          "originalWidth": 400,
          "originalHeight": 263,
          "caption": "(PRNewsfoto/IDEAYA Biosciences, Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ys1P59VsmJC82_UFYSirrw--~B/aD0yNjM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/74efd2e2f7cc28d3a6ce5efb40fb6e7d.cf.webp",
              "width": 400,
              "height": 263,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZgYI.dEk9PGbPMvsgTfH.A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/74efd2e2f7cc28d3a6ce5efb40fb6e7d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ideaya-biosciences-completes-targeted-full-110000631.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ideaya-biosciences-completes-targeted-full-110000631.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IDYA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]